Results 21 to 30 of about 355,625 (242)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.

PLoS ONE, 2022
Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes.
Sweta M Patel, Yazdani B Shaik-Dasthagirisaheb, Morgan Congdon, Rebecca R Young, Mohamed Z Patel, Tiny Mazhani, Sefelani Boiditswe, Tirayaone Leburu, Kwana Lechiile, Tonya Arscott-Mills, Andrew P Steenhoff, Kristen A Feemster, Samir S Shah, Coleen K Cunningham, Stephen I Pelton, Matthew S Kelly   +15 more
doaj   +3 more sources

A pediatric case series of invasive pneumococcal disease caused by S.Pneumonia serotype-19A despite full dose vaccination

Human Vaccines & Immunotherapeutics, 2023
Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and bacterial meningitis in children. Although pneumococcal conjugate vaccines (PCVs) are commonly available, invasive pneumococcal disease (IPD) still remains a life ...
Burcu Ceylan Cura Yayla, Tugba Bedir Demirdag, Emine Akkuzu, Nursel Kara, Hasan Tezer, Anıl Tapisiz   +5 more
doaj   +1 more source

Changes in the Features of Invasive Pneumococcal Disease after Introduction of the Seven-valent Pneumococcal Conjugate Vaccine in a Regional Core Hospital of Kochi, Japan [PDF]

, 2015
Since the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2007, invasive pneumococcal disease has declined, but the incidence of Streptococcus pneumoniae serotype 19A has risen worldwide.
Akane Kanazawa, Chiho Tokorodani, Hidehiko Maruyama, Hirokazu Watanabe, Hiroyuki Miyahara, Kiyoshi Kikkawa, Mari Miyazawa, Ritsuo Nishiuchi, Yuka Iwasaki, Yusei Nakata, Yusuke Shigemitsu   +10 more
core   +1 more source

Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines Against Invasive Pneumococcal Disease

Pediatrics, 2020
Two PCVs are licensed for prevention of pneumococcal disease. Uncertainty about the effectiveness against AOM and serotype 19A invasive disease in children ≤5 years remains.
Melissa Berman-Rosa, Shauna O’Donnell, Mackenzie Barker, C. Quach   +3 more
semanticscholar   +1 more source

Impact of COVID-19 Nonpharmaceutical Interventions on Pneumococcal Carriage Prevalence and Density in Vietnam

Microbiology Spectrum, 2023
Nonpharmaceutical interventions (NPIs) implemented to contain SARS-CoV-2 have decreased invasive pneumococcal disease. Previous studies have proposed the decline is due to reduced pneumococcal transmission or suppression of respiratory viruses, but the ...
Monica Larissa Nation, Sam Manna, Hau Phuc Tran, Cattram Duong Nguyen, Le Thi Tuong Vy, Doan Y. Uyen, Tran Linh Phuong, Vo Thi Trang Dai, Belinda Daniela Ortika, Ashleigh Christina Wee-Hee, Jemima Beissbarth, Jason Hinds, Kathryn Bright, Heidi Smith-Vaughan, Thuong Vu Nguyen, Kim Mulholland, Beth Temple, Catherine Satzke   +17 more
doaj   +1 more source

A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population

Pathogens, 2020
Adult vaccination is high on the agenda in many countries. Two different vaccines are available for the prevention of pneumococcal disease in adults: a 23-valent polysaccharide vaccine (PPV23), and a 13-valent conjugated vaccine (PCV13). The objective of
J. D. Berild, B. Winje, D. Vestrheim, H. Slotved, P. Valentiner-Branth, A. Roth, Jann Storsäter   +6 more
semanticscholar   +1 more source

Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain

Emerging Infectious Diseases, 2022
We analyzed the effect of COVID-19 on healthcare demand and invasive pneumococcal disease in children in Catalonia, Spain. Compared with 2018–2019, we noted large reductions in healthcare activities and incidence of invasive pneumococcal disease in 2020.
Pilar Ciruela, Núria Soldevila, Juan José García-Garcia, Sebastià González-Peris, Alvaro Díaz-Conradi, Alba Redin, Belén Viñado, Conchita Izquierdo, Carmen Muñoz-Almagro, Angela Domínguez   +9 more
doaj   +1 more source

Acquisition of pneumococci specific effector and regulatory Cd4+ T cells localising within human upper respiratory-tract mucosal lymphoid tissue [PDF]

, 2011
The upper respiratory tract mucosa is the location for commensal Streptococcus (S.) pneumoniae colonization and therefore represents a major site of contact between host and bacteria.
AD Reynolds, AM Faria, C Jokinen, C Laine, C O'Mahony, Carlos Javier Orihuela, D Bogaert, DM Musher, EJ Novak, EK Mulholland, EM Laughlin, G Oldenhove, H Christensen, HM Foy, HW Lim, I Rudan, JC Paton, Jeffrey Pido-Lopez, JL Round, JN Stoop, K Wing, KA Robinson, L Strauss, L Weiss, M Hara, M Hussain, M Lipsitch, M Livingston, M Quigley, MJ Butte, MJ van Kempen, MW Mureithi, N Iikuni, Neil A. Williams, PC Hill, PR Myles, Q Zhang, Q Zhang, Q Zhang, R Austrian, R Malley, R Malley, RM Wong, Robert S. Heyderman, S Hori, S Paust, S Rapola, S Read, S Sakaguchi, S Sakaguchi, SE Sandner, SK Obaro, SQ Crome, T Sturniolo, T Takahashi, Timothy J. Mitchell, V Davenport, William W. Kwok, X Zhang, Y Belkaid, Y Cong, YJ Lu, Z Zhang   +62 more
core   +3 more sources

Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies

Lancet Global Health, 2020
Summary Background The population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13) in 2011, we examined its impact on vaccine and non-vaccine serotype
N. Bar-Zeev, T. Swarthout, D. Everett, M. Alaerts, J. Msefula, C. Brown, Sithembile Bilima, J. Mallewa, Carina King, A. von Gottberg, J. Verani, C. Whitney, C. Mwansambo, S. Gordon, N. Cunliffe, N. French, R. Heyderman   +16 more
semanticscholar   +1 more source

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. [PDF]

, 2010
BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa.
French, N, Gilks, CF, Gordon, SB, Longwe, H, Molyneux, ME, Mwafulirwa, G, Mwaiponya, M, Mwalukomo, T, White, SA, Zijlstra, EE   +9 more
core   +2 more sources